Vivani Medical Completes Dosing of All 20 Patients in SLIM-1 Phase 1 Trial for Semaglutide Implant; Top-Line Data Expected November 2026
VANI sits 52% above its 52-week low of $0.923 on light trading volume (0.2× avg).
Summary
Vivani Medical has completed dosing of all 20 participants in its SLIM-1 Phase 1 trial for the NPM-139 semaglutide implant, with top-line data expected in November 2026. The trial remains on track and ahead of schedule, supporting advancement to a Phase 2 dose-ranging study in 2027.
Key Events · Product Development and Regulatory · VANI
-
SLIM-1 Trial Fully Enrolled and Dosed
All 20 participants in the Phase 1 SLIM-1 trial for the NPM-139 semaglutide implant have been dosed. The first 10 were dosed on July 29, 2026, ahead of schedule, and the remaining 10 one week later. All insertion procedures were completed successfully without issues.
-
Top-Line Data Expected November 2026
The company expects to report top-line safety, tolerability, and pharmacokinetic data from the 20-participant trial in November 2026, which will guide initiation of a Phase 2 dose-ranging trial in 2027.
-
Novo Nordisk Evaluation Agreement Backdrop
This milestone follows a July 2026 agreement with Novo Nordisk to internally evaluate NPM-139 and Vivani's NanoPortal implant technology, providing external validation of the platform.
-
Competitive Positioning in GLP-1 Obesity Market
NPM-139 is designed for once- or twice-yearly administration, aiming to improve convenience, adherence, and tolerability over daily or weekly GLP-1 therapies. Preclinical studies showed sustainable 20% weight reduction in animal models.
Analysis · VANI · Industrial Applications And Services
Vivani Medical has fully enrolled and dosed all 20 participants in its SLIM-1 Phase 1 trial for NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Dosing began ahead of schedule on July 29 and was completed without issues. This milestone de-risks the clinical timeline and sets the stage for top-line data in November 2026, which will inform a planned Phase 2 dose-ranging trial in 2027. The news follows a July 2026 agreement with Novo Nordisk to evaluate the implant technology, reinforcing external validation. For a $119M market-cap biotech, successful execution of a first-in-human trial for a GLP-1 implant in the competitive obesity space is a significant value driver.
At the time of this filing, VANI was trading at $1.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $119M. The 52-week trading range was $0.92 to $1.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.